B+
Bull case
30%
Probability
Target price
$7.50
Analysis reference price unavailable
Analysis 2026-05-09 · RankAlpha Sentiment Codex
PGEN
PrecigenFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Primary-source evidence improved versus the prior baseline: PAPZIMEOS is approved, Q4 2025 included the first partial quarter of US sales, management described stronger Q1 2026 demand, broad payer access, and a permanent J-code effective April 1, 2026, which together support a real commercialization path [#PR-2026-03-25].
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.1.
What can break
Balance-sheet risk remains material for a small biopharma: the 10-K shows $100.0 million of long-term debt and an operating loss in 2025, so weaker uptake could reopen financing concerns [#10-K-2026-03-25].
Momentum
85
Value
41
Sentiment
29
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.40 · Bull $7.50 · Bear $2.10Analysis 2026-05-09; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-09 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $13.67
Why
Momentum85 · Δ7d -6.5
Value41 · Δ7d -0.1
Sentiment29 · Δ7d +3.6
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.1.
Contradictions & invalidation
- • Balance-sheet risk remains material for a small biopharma: the 10-K shows $100.0 million of long-term debt and an operating loss in 2025, so weaker uptake could reopen financing concerns [#10-K-2026-03-25].
- • EMA review and redosing work are promising but timing and outcome are uncertain, limiting near-term non-US downside protection [#PR-2026-03-25].
- • The thesis is still narrow because PGEN is now heavily dependent on one launch, broader pipeline timing is thin, paused PRGN-3005 and PRGN-3007 programs reduce diversification, and the 10-K still frames continued operations as dependent on execution, revenue generation, and access to capital if needed [#10-K-2026-03-25].
Catalyst clock
2026-05-15
First post-launch 10-Q should test whether PAPZIMEOS demand is converting into repeat revenue
Lead driver: Value · See fundamentals
Momentum
85
8% active weight
Current posture
7d trendSoftening
Δ7d
-6.5
Δ21d
-7.0
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
29
45% active weight
Current posture
7d trendImproving
Δ7d
+3.6
Δ21d
+20.5
Why this grade
Composite grade F. Momentum 85.4 / Value 40.6 / Sentiment 28.6
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-09. Scenario method
Most likely
B
Base case
40%
Probability
Target price
$4.40
Analysis reference price unavailable
Analysis 2026-05-09 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$2.10
Analysis reference price unavailable
Analysis 2026-05-09 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$2.22B
Beta
1.07
Shares Out
358.04M
P/E (TTM) · Derived
-4.5
P/S (TTM)
234.42
P/FCF (TTM) · Derived
-18.72
Rev YoY
+6322.7%
EPS YoY
-153.9%
Gross Margin
+89.2%
Op Margin
-46.1%
Net Debt
$432K
Current Ratio
4.58
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data